Loading
A phase 1/2 trial of Toripalimab in sarcomas, run by Ascentage Pharma Group Inc., now recruiting.
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04785196 by Ascentage Pharma Group Inc., with 95 participants planned, started 2021-05-26 and due to reach its primary completion in 2026-04. Interventions recorded: APG-115 and Toripalimab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Toripalimab, Sarcomas (soft tissue, bone, GIST), Immune checkpoint inhibitors and the tag pipeline.
Shares Toripalimab, Immune checkpoint inhibitors and the tag pipeline.
Shares Ascentage Pharma and the tag pipeline.
Shares Liposarcoma, Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Toripalimab, Immune checkpoint inhibitors and the tag pipeline.
Shares Ascentage Pharma and the tag pipeline.
Shares Toripalimab, Immune checkpoint inhibitors and the tag pipeline.
Shares Toripalimab, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/